Advance care planning for a child with a life-limiting illness — parental authority, the child's own voice, and concurrent curative + hospice care
Pediatric medicine does not operate on the adult model of individual informed consent. Because minors generally lack full legal capacity, parents or legal guardians act as surrogate decision-makers — but modern pediatric palliative care insists that a seriously ill child is never merely a passive object of someone else's decisions. The central task of Stage 1 is building a decision-making structure that honors parental legal authority while actively eliciting the child's own developmentally-appropriate voice.
The American Academy of Pediatrics' 1995 policy statement "Informed Consent, Parental Permission, and Assent in Pediatric Practice" — reaffirmed and updated in 2016 — deliberately replaced the term "informed consent" with "parental permission" for medical decisions involving minors. This is not a semantic quibble: it signals that the legal and ethical authority parents exercise is a form of guardianship exercised in the child's best interest, not a personal right to consent on their own behalf as they would for their own body.
In nearly every U.S. jurisdiction, parents or legal guardians are the default surrogate decision-makers for a minor's medical care, including decisions to initiate, continue, limit, or withdraw life-sustaining treatment. This authority is broad but not absolute: courts can and do intervene when parental decisions appear to place a child at clear risk of serious harm, and hospital ethics committees frequently mediate disputes between families and clinical teams over resuscitation status, treatment escalation, or withdrawal of support.
A patchwork of "mature minor" doctrines — recognized through specific statutes in some states and through case law in others — allows minors (typically age 14 and older, though the threshold varies) to consent independently to certain categories of care, such as reproductive health, mental health treatment, or substance use treatment. Only a minority of these doctrines extend cleanly to decisions about life-sustaining treatment for a life-limiting illness, and application to that context remains legally unsettled and inconsistent across states — which is why palliative teams document assent processes carefully even where they lack independent legal force.
Myra Bluebond-Langner's landmark ethnographic work with children dying of leukemia (The Private Worlds of Dying Children, 1978) found that most children — even those never told their diagnosis or prognosis directly — accurately inferred the seriousness of their illness from clinical cues, changes in adult behavior, and the experiences of other hospitalized children. Many engaged in "mutual pretense" with parents and staff, each side avoiding the topic to protect the other. This remains a foundational finding: silence does not equal ignorance, and it often isolates the child at exactly the moment they most need connection.
A child's capacity to understand illness, death, and treatment choices develops in a broadly predictable sequence, though individual variation — driven by illness experience, cognitive ability, culture, and family communication style — is substantial and must always take precedence over age-based assumptions.
Infants and toddlers (0–3 years) have no capacity for verbal assent; care planning focuses entirely on comfort, attachment, and parental proxy decision-making, informed by behavioral distress cues.
Preschool children (roughly 3–7 years, Piaget's preoperational stage) often understand illness in magical or punitive terms ("I got sick because I was bad") and may not grasp the permanence of death. Communication uses concrete, play-based methods — medical play, drawing, dolls — rather than abstract discussion.
School-age children (roughly 7–11 years, concrete operational stage) develop a much more literal, biological understanding of illness and can grasp that death is permanent, universal, and irreversible — though they may not yet reason abstractly about probability or long-term consequence. This is the age range at which most pediatric ethics guidance recommends actively seeking assent: explaining what will happen in language the child can understand, assessing the child's understanding, eliciting their willingness, and respecting a sustained, clearly expressed objection where clinically feasible.
Adolescents (roughly 11 years and older, formal operational stage) can reason abstractly about prognosis, risk, and future-oriented consequences, and increasingly resemble adults in decisional capacity — even though they typically remain legal minors. Many pediatric palliative programs treat older adolescents as functional co-decision-makers alongside parents, particularly around quality-of-life tradeoffs the adolescent alone experiences directly, such as fatigue from ongoing chemotherapy versus disease control.
Palliative teams use structured but flexible approaches to build the child into the decision-making process without displacing parental authority:
• The "three-legged stool" model treats child, parent(s), and clinical team as three necessary participants, with the balance of voice shifting toward the child as developmental capacity and illness experience grow.
• Assent conversations are documented separately from parental permission — noting what was explained, in what terms, what the child appeared to understand, and whether the child expressed a preference or objection — creating a longitudinal record the team can revisit as understanding deepens.
• Play therapists and child life specialists translate abstract medical concepts (a central line, a feeding tube, what chemotherapy does) into terms a young child can process, using medical play, picture books, and normalization techniques that reduce fear and increase the child's sense of control.
• For adolescents with a terminal trajectory, structured tools (see Stage 2) provide a private, low-pressure format for expressing wishes that may be difficult to say aloud in front of parents — wishes about who should be present at the end, what environment feels comforting, and what legacy they want to leave.
Throughout, the guiding ethical principle is proportionality: the more consequential and irreversible a decision, and the more mature the child's reasoning, the greater the weight the child's own voice should carry — always in dialogue with, not substitution for, parental judgment and love.
Adult advance directive instruments like Five Wishes were never designed for a nine-year-old or a seventeen-year-old facing a terminal diagnosis. Over the past two decades, pediatric palliative care has developed its own family of structured communication tools — pictorial for young children, narrative and values-based for adolescents and young adults — alongside condition-specific care plans built around the distinct trajectories of the diseases most likely to bring a child to end-of-life planning.
Aging with Dignity, the organization behind the widely used adult Five Wishes advance directive, developed two pediatric-oriented companion tools in response to demand from pediatric palliative programs:
"Voicing My Choices" (2012) is designed for adolescents and young adults living with serious illness, typically used from around age 16 upward, though many programs introduce it earlier for mature younger adolescents. It is explicitly not a legal document in most states — it does not carry the binding force of a completed advance directive — but functions as a structured values conversation covering: how the young person wants to be comforted, who they want making decisions and present at key moments, what makes them feel like themselves even when very sick, spiritual and personal beliefs, and how they wish to be remembered. Its non-legal, narrative format lowers the barrier to completion and gives clinicians and family a durable record of the adolescent's own words.
"My Wishes" is a simpler, more pictorial adaptation aimed at younger children, roughly ages 8 through the young teen years, using checkboxes, drawing prompts, and concrete questions ("Who do you want to have with you?" "What makes you feel better when you don't feel good?") rather than abstract medical or legal language. It is deliberately low-stakes and can be completed collaboratively with a parent, child life specialist, or social worker over multiple short sessions.
Both tools share a common design philosophy: they meet the child where their language and conceptual development actually are, they are revisited rather than completed once, and they exist to open conversation rather than to force premature or permanent decisions.
Because different life-limiting pediatric conditions have very different trajectories, palliative teams build condition-specific anticipatory guidance into the planning process rather than relying on generic templates:
Diffuse intrinsic pontine glioma (DIPG): a brainstem tumor with a median survival of roughly 9–11 months from diagnosis and a five-year survival under 10%, making it one of the few pediatric diagnoses where a near-uniformly fatal course is known at diagnosis. Because the trajectory is predictable, DIPG programs typically front-load advance care planning conversations early — often at diagnosis or shortly after radiation — addressing corticosteroid taper and its neurologic consequences, the progressive loss of motor, speech, and swallowing function, and preferred location of care and death, well before a crisis forces rushed decisions.
Complex congenital heart disease (single-ventricle physiology, hypoplastic left heart syndrome and similar lesions): children undergo staged surgical palliation (e.g., Norwood, Glenn, Fontan procedures) with meaningful risk of sudden cardiac death, arrhythmia, and progressive heart failure at any stage. Planning here often includes explicit discussion of resuscitation limits in the cardiac ICU, and — for children with implanted pacemakers or defibrillators — advance planning for device deactivation when the goals of care shift toward comfort, since an active defibrillator can deliver painful shocks during an otherwise peaceful dying process if not proactively addressed.
Severe neuromuscular disease (spinal muscular atrophy type 1, advanced Duchenne muscular dystrophy): progressive respiratory muscle weakness drives the central decision point — whether and when to escalate from non-invasive support to tracheostomy and long-term invasive ventilation. Because this decision fundamentally shapes the remainder of the child's life and the family's caregiving burden, programs aim to have the conversation well before an acute respiratory crisis forces an emergency choice under pressure.
The disease-modifying therapy landscape for spinal muscular atrophy (nusinersen, onasemnogene abeparvovec, risdiplam, all approved 2016–2020) has meaningfully shifted prognosis for many SMA type 1 infants — a reminder that pediatric advance care planning tools and condition-specific guidance must be revisited regularly, since a diagnosis once considered uniformly fatal in infancy may now carry a substantially different trajectory.
Unlike a typical adult advance directive, which is often completed once and stored, pediatric advance care planning is understood as an iterative, longitudinal process. Plans are explicitly revisited at predictable trigger points: at initial diagnosis, at disease progression or a new prognostic milestone, at developmental transitions (a young child aging into adolescence and increasing decisional capacity), around major treatment decisions (a new clinical trial, a surgical option, a transplant evaluation), and at any point the family or care team senses that circumstances or the child's own wishes may have shifted.
Documentation practice reflects this: rather than a single signed form, many programs maintain a living care plan summary — updated at each significant conversation — that travels with the child across care settings (inpatient, outpatient, emergency department, school, home) so that whoever is caring for the child in a crisis has access to the most current understanding of the family's and child's wishes, not a stale snapshot from months or years earlier.
For decades, the U.S. hospice benefit — built on the 1982 Medicare Hospice Benefit model — required patients to forgo curative or life-prolonging treatment related to their terminal diagnosis in exchange for hospice services, alongside a physician certification of a six-month-or-less prognosis. Applied to children, this created what pediatric palliative clinicians came to call "the terrible choice": a family could accept hospice support only by giving up any remaining chance, however small, of a cure. The Affordable Care Act eliminated that trade-off for the nation's Medicaid- and CHIP-enrolled children.
Section 2302 of the Affordable Care Act, sometimes referred to as the "Concurrent Care for Children" requirement, amended Section 1905(o) of the Social Security Act. It requires that state Medicaid programs — and, through cross-reference, CHIP programs — pay for hospice care for a child under age 21 concurrently with curative or life-prolonging treatment related to the child's terminal condition, rather than forcing an election between the two.
Before this change, pediatric hospice eligibility mirrored the adult Medicare Hospice Benefit almost exactly: a physician certification of a prognosis of six months or less if the disease ran its normal course, and a formal election of the hospice benefit that waived coverage for curative treatment of the terminal condition. For a child with, say, relapsed leukemia still eligible for an experimental protocol, or a DIPG patient still receiving palliative radiation, this waiver requirement was often an impossible ask for families and clinicians alike — and it meant many children who would have benefited enormously from hospice's interdisciplinary support (nursing, symptom management, chaplaincy, social work, respite, bereavement care) were never referred until treatment options were fully exhausted, often in the final days of life.
Section 2302 removed the waiver requirement for Medicaid/CHIP-enrolled children specifically. A child can now be formally enrolled in hospice — gaining access to its full interdisciplinary support structure — while simultaneously continuing chemotherapy, radiation, dialysis, or another disease-directed treatment aimed at cure or life prolongation.
The concurrent care provision applies to children covered by Medicaid and the Children's Health Insurance Program (CHIP) — the payers covering close to half of all U.S. children. It does not create a federal mandate for private commercial insurers to offer concurrent coverage, so a family's actual access to concurrent care still depends significantly on their insurance type, and many pediatric palliative programs report ongoing advocacy work convincing individual private payers to authorize concurrent coverage on a case-by-case basis.
The practical effect of concurrent eligibility has been significant where it applies. Families can accept hospice enrollment — and the home nursing visits, 24/7 symptom-management phone support, medical equipment coverage, chaplaincy, expressive therapies, and respite care that come with it — without any sense that doing so means giving up on their child or abandoning active treatment.
This has measurably changed referral patterns: pediatric hospice and palliative programs report that concurrent-eligible children are referred earlier in their disease course and remain enrolled in hospice longer than historical pre-ACA cohorts, because the psychological and practical barrier of "electing" hospice at the cost of treatment has been removed. Longer length of stay in hospice care is strongly associated with better symptom control, more advance care planning completed proactively rather than in crisis, and better-supported families at the time of death.
It also changes the clinical conversation itself. Rather than palliative and hospice referral being coupled to a message of "there is nothing more we can do," concurrent eligibility allows the message to be "we can add another layer of support while we keep treating" — a framing many oncologists, cardiologists, and intensivists find considerably easier to introduce to families early, rather than delaying until treatment options are exhausted.
Despite the legal change, several structural barriers limit how fully concurrent care reaches the children who could benefit:
• Coverage gap: children covered by private commercial insurance rather than Medicaid/CHIP have no federal guarantee of concurrent coverage; access depends on individual payer policy and case-by-case negotiation.
• Hospice agency capacity: many community hospice agencies are built around an adult, cancer-predominant patient population and have limited clinical experience with technology-dependent pediatric patients — children on home ventilators, parenteral nutrition, or complex seizure regimens — creating access gaps, particularly in rural areas with few or no pediatric-experienced hospice providers.
• Workforce shortage: the number of physicians and advanced practice providers with formal pediatric hospice and palliative medicine subspecialty training remains small relative to national need, constraining both direct clinical capacity and the availability of expert consultation to support community hospice agencies caring for medically complex children.
• Care coordination complexity: concurrent care by design requires close, ongoing coordination between the child's disease-directed specialty team (oncology, cardiology, neurology) and the hospice interdisciplinary team — a level of cross-team communication that is logistically harder to sustain than the cleaner handoff of a traditional either/or hospice election, and that varies considerably in quality across institutions and regions.
A child's illness is never contained within the child alone — it reorganizes an entire family system: siblings absorb disrupted routines and divided parental attention, schools must adapt to a classmate's medical complexity and frequent absence, and parents carry cumulative psychosocial, financial, and spiritual strain over months or years. Comprehensive pediatric advance care planning treats the family, not just the patient, as the unit of care.
For a child able to attend school at all during serious illness, school is often one of the last remaining spaces of normalcy — ordinary routine, peer relationships, and an identity not solely defined by illness. Pediatric palliative teams work with families and school personnel (school nurse, counselor, teachers, administrators) to build an Individualized Healthcare Plan (IHP), sometimes layered with a formal 504 Plan or Individualized Education Program (IEP) under U.S. education law when the illness affects learning access.
A typical IHP addresses: medication administration during school hours, emergency action plans for seizures, port/line care, or acute deterioration, accommodations for fatigue and reduced stamina (rest breaks, modified schedules, elevator access, reduced course load), a plan for medical re-entry after extended treatment absence (chemotherapy blocks, transplant admission, surgical recovery), options for home or hospital-based instruction when in-person attendance is not possible, and — for classmates and staff — age-appropriate guidance for how the illness will be discussed, respecting the family's and child's preferences for privacy versus openness.
For children whose illness is expected to be terminal, some programs additionally develop a sensitive protocol for how the school community will be informed and supported if the child dies while still enrolled — including support for the child's classmates and teachers, who often experience real grief of their own.
A substantial body of pediatric psychosocial literature — building on early work by researchers such as Betty Davies on sibling bereavement — documents that siblings of a seriously ill child are themselves a vulnerable population, often described as "living in the shadow" of the ill child's needs. Across studies, roughly 30–40% of siblings show clinically significant symptoms of anxiety, depression, or behavioral change during a brother's or sister's serious illness, driven by disrupted routines, reduced parental availability, unclear or absent information about what is happening, and — for many — profound but often unspoken fear and guilt, including a common (and clinically important) sense of "survivor guilt" both during the illness and after a death.
Siblings are frequently under-informed relative to what they sense and imagine, echoing the same "mutual pretense" dynamic seen in ill children themselves: well-meaning adults, trying to protect a sibling from pain, often leave that sibling more frightened and isolated by silence than they would be with honest, developmentally appropriate information.
Structured sibling support has become a standard component of comprehensive programs: age-appropriate honest communication about the illness and prognosis, involvement in caregiving tasks appropriate to developmental stage (which restores a sense of agency and connection rather than helplessness), and peer support programs such as the Sibshops model (developed by Don Meyer and the Sibling Support Project) — recreational, facilitated peer workshops that give siblings of children with chronic illness or disability a space explicitly built around their own experience rather than their brother's or sister's diagnosis.
Sibling bereavement outcomes are strongly shaped by whether the sibling was included, informed, and given a defined role during the illness itself — not only by support offered after a death. Programs that engage siblings early, rather than only in bereavement, consistently report better long-term adjustment.
Caring for a child with a life-limiting illness places sustained strain on the entire family system, and comprehensive programs build support across several domains simultaneously:
• Psychosocial and caregiver strain: parents of seriously ill children report elevated rates of anxiety, depression, and post-traumatic stress, along with significant strain on the parental relationship itself; social work and psychology support is directed at both individual parents and the couple/family unit.
• Financial toxicity: studies of pediatric serious illness consistently find that a majority of families experience a reduction in household income, driven by a parent reducing work hours or leaving employment to provide caregiving, combined with rising out-of-pocket costs for travel, lodging near treatment centers, and non-covered services — financial counseling and connection to assistance programs is now considered a core, not optional, component of comprehensive care.
• Respite care: because caregiving for a technology-dependent or medically fragile child is physically and emotionally exhausting and largely continuous, hospice benefit models (including the federal structure many state pediatric hospice benefits are built on) typically include a respite provision — commonly up to five days of inpatient respite per benefit period — allowing family caregivers scheduled recovery time.
• Spiritual and cultural care: chaplaincy and attention to the family's specific cultural and religious frameworks for illness, suffering, and death are integrated into care planning, since these frameworks often shape what families consider an acceptable or meaningful death, and what rituals matter at end of life.
Pediatric advance care planning ultimately branches toward one of two very different horizons. For the growing population of children who survive childhood with complex chronic conditions, planning turns toward a structured transition into adult-oriented healthcare systems. For those whose illness follows a terminal trajectory, planning turns toward the concrete decisions of dying — resuscitation status, preferred location of death, and the deliberate, evidence-supported practice of legacy-building.
Medical progress has transformed the population of children with historically fatal or severely life-limiting congenital and chronic conditions: childhood cancer five-year survival now approaches 85% in aggregate (up from roughly 58% in the 1970s), and — a striking marker of this shift — there are now more adults living with congenital heart disease in the United States than children, because survival into and through adulthood has become the expectation rather than the exception for many lesions once considered uniformly fatal in infancy.
This success creates its own advance-planning task: transitioning a young adult, raised within a pediatric care model built around parental proxy decision-making, into an adult-oriented healthcare system that expects the patient to be the primary decision-maker and legal owner of their own advance directives. The most widely adopted framework is "Got Transition's" Six Core Elements of Health Care Transition (endorsed in a 2018 clinical report by the American Academy of Pediatrics, American College of Physicians, and American Academy of Family Physicians): (1) an explicit transition policy communicated early, (2) systematic tracking and monitoring of transition progress, (3) assessment of the young person's transition readiness and self-management skills, (4) transition planning including a medical summary and emergency care plan, (5) formal transfer of care to an adult provider, and (6) confirmation that transfer was completed and the new relationship established.
The transition is often clinically harder than it sounds: adult subspecialists with deep experience in a given congenital or complex childhood condition (adult congenital heart disease clinics, for example) remain relatively scarce, and the young adult must simultaneously take on legal decisional authority — including establishing their own advance directive as an adult patient, potentially for the first time revisiting decisions their parents made on their behalf for years.
For children whose illness is expected to be fatal, advance care planning moves into concrete, often difficult territory:
• Resuscitation status: conversations about whether to pursue full resuscitation, a limited intervention, or to "allow natural death" at the time of cardiopulmonary arrest. Many states support an out-of-hospital do-not-resuscitate order or a broader pediatric medical orders form (state-specific analogs of the adult POLST/MOLST model) that travels with the child across settings — home, school, ambulance, emergency department — so that resuscitation wishes are honored consistently regardless of where a crisis occurs.
• Preferred location of death: across family surveys, a majority express a preference for death at home when adequate nursing, equipment, and symptom-management support is available, though actual home death rates vary considerably by region, diagnosis, and access to pediatric-experienced home hospice services; some families instead prefer an inpatient hospice unit or hospital setting for reasons of safety, symptom complexity, or personal comfort, and there is no single "correct" answer — the goal is an informed, supported choice rather than a default.
• Symptom priorities in the final days and weeks: anticipatory guidance and proactive symptom-management planning for pain, dyspnea, terminal secretions, and agitation, so that medications and equipment are already in place at home before a crisis rather than requiring an emergency response.
• Presence and ritual: planning for who the family wants present at the time of death, and what cultural, religious, or personal rituals matter — music, specific people, particular objects, faith practices — treated as a core part of the care plan, not an afterthought.
A distinct and well-evidenced component of pediatric end-of-life care is deliberate legacy-building: structured activities that create tangible connections between the child and their family that persist after death. Common interventions include handprint or footprint molds and castings, memory boxes containing meaningful objects, recorded video or audio messages, "heartbeat" recordings, art and writing projects, and structured "life story" work undertaken with a child life specialist or psychosocial counselor.
Studies of bereaved parents consistently associate participation in legacy-building activities with more adaptive longer-term grief outcomes — these objects and recordings become durable anchors for what grief researchers call "continuing bonds," an ongoing relationship with the deceased child that coexists with, rather than blocks, healthy adaptation to loss.
Bereavement support does not end at the moment of death: consistent with the broader hospice model, pediatric hospice and palliative programs typically provide structured family bereavement follow-up for at least thirteen months after a child's death — covering the full first year of anniversaries and milestones — including check-ins, support groups, and referral to specialized grief counseling, with particular attention to surviving siblings and to parents, whose grief following the death of a child is recognized in the bereavement literature as among the most severe and prolonged forms of loss.
Legacy-building is not reserved for the final days. Many programs begin these activities early in a terminal trajectory — sometimes months before death — so that the process is unhurried, collaborative, and, whenever developmentally appropriate, led in part by the child's own choices about how they want to be remembered.